News
Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.
Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.
While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...
They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and—in data ...
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...
Roche plans to invest over $700 million in setting up a new plant in North Carolina and up to $550 million in expanding its Indianapolis diagnostics hub.
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...
GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results